Both in Pharmaceuticals
Neurogene vs Climb Bio
Over the past year NGNE returned −13.6% and CLYM returned +369.0%; their daily moves had a correlation of 0.26.
NGNE −13.6% CLYM +369.0%Growth of $1, one year, split-adjusted
| Metric | NGNE | CLYM |
|---|---|---|
| Price | $26.85 | $9.38 |
| Market cap | $537.3M | $538.8M |
| Today | +0.67% | −3.79% |
| 1 month | +5.5% | −12.2% |
| 6 months | −17.0% | −23.2% |
| Year to date | +30.3% | +134.5% |
| 1 year | −13.6% | +369.0% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $225.4M | $183.1M |
| Dividend yield | — | — |
| Volatility (60d) | 76.3% | 80.8% |
| Short % of float | 39.6% | 25.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).